Drugs / Daratumumab
Daratumumab
Drug FDA approvedMarketed as Darzalex
Human monoclonal antibody targeting CD38·First approved·2015·1 brand
- Registered trials
- 260
- Ongoing
- 140/ 54%
- Completed
- 71
- Indications
- 1
Approved indications by brand
| Brand | Indication |
|---|---|
| Darzalex | Multiple myeloma |
Clinical trial landscape
260 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 113 | 61 | 26 | |
| Phase 3 | 47 | 34 | 11 | |
| Phase 1 | 42 | 16 | 17 | |
| Phase 1/2 | 32 | 17 | 8 | |
| Unknown | 8 | 1 | 5 | |
| Phase 2/3 | 6 | 3 | 2 | |
| Not applicable | 5 | 3 | 0 | |
| Phase 4 | 4 | 3 | 1 | |
| Early Phase 1 | 3 | 2 | 1 | |
| All phases | 260 | 140 | 71 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Binds CD38 and induces tumor-cell elimination via ADCC, CDC, ADCP, and apoptosis-related immune effector mechanisms.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.